# Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

> **NCT02447887** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- RCC

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Pegylated IFN-alpha 2b

## Key facts

- **NCT ID:** NCT02447887
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-14
- **Primary completion:** 2017-04-25
- **Final completion:** 2017-04-25
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** IRB study closure facilitated by Investigator
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02447887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02447887, "Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02447887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*